BioSpace News Archive

This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer

AngioDynamics, Inc. announced that the United States District Court for the District of Delaware, on day four of a jury trial at the close of C.R. Bard’s case, granted judgement as a matter of law under rule 50 in favor of AngioDynamics, dismissing Bard’s suit alleging that certain of AngioDynamics’ implantable port products infringed three Bard patents.

Le Bonheur Children’s Hospital announced that Michael Wiggins, MBA, FACHE, will become its next president.

2019 contribution highlights awareness of breast cancer prevention with a new blog post series

Experts from the ProfNet network who are available to discuss timely issues in your coverage area.

Advancements in the dynamic field of biotechnology are bringing about the development of innovative, new food products.

Latest in series of Government actions to protect Canadians from exposure to lead

The FDA issued a Letter to Health Care Providers to alert them that the agency is aware of an increasing number of medical device reports associated with the use of surgical staplers for internal use and implantable surgical staples—common devices used in many surgeries—and to provide updated recommendations to help reduce risks associated with their use.

GRYYT, LLC, a social impact intelligence company focused on impacting the world’s greatest socioeconomic and quality of life challenges, announced their commitment to addressing and combating the U.S. drug epidemic.

Validation Institute, an organization focused on delivering better health value and stronger outcomes than conventional healthcare, announced that EmpiRx Health has been selected as a finalist for a Health Value Award in the Pharmaceutical Benefits Manager category.